Betta Pharmaceuticals announces three of its products have been included in the National Essential Medicines List (2026 Edition). This inclusion, particularly for the new inclusion of Bevazumab, signifies strong clinical recognition. The listing is expected to enhance drug accessibility and positively impact sales by leveraging policy support for tiered healthcare and integrated medical systems.
Summary generated by AI · Always verify with source document
Securities Code: 300558
Securities Abbreviation: Betta Pharmaceuticals
Announcement No.: 2026-045
Betta Pharmaceuticals Co., Ltd.
Announcement on Company Products Included in the National Essential Medicines List (2026 Edition)
The Company and the entire Board of Directors guarantee that the information provided herein is true, accurate, and complete, and contains no false records, misleading statements, or material omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.